Capital Patents Pricing San Diego 
TechCrunch LA
MARCH 22, 2018
We’ve also seen a substantial inflow of venture capital from all over the world.”. Our research revealed a saturation level causing unprecedented challenges, starting with exorbitant housing prices and runaway operating costs that accelerate a startup’s “burn rate”—its monthly spending.
Xconomy
DECEMBER 14, 2018
Pharmaceutical industry critics lament the cost of rare disease drugs, but some of the steepest price hikes have come on widely used insulin. The patent holder, the University of Toronto, gave companies the right to manufacture insulin. to offer competitive pricing pressure. to offer competitive pricing pressure.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
SEPTEMBER 6, 2019
Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have to steal away. But the first mover isn’t infallible if someone else has something better. is counting on.
Xconomy
JULY 26, 2019
What will the legacy be of Jeff Leiden, the longtime CEO of Vertex Pharmaceuticals? Vertex surprised Wall Street this week by announcing Leiden’s seven-year run will end next spring. In some ways, his legacy is already written. He steered Vertex through a crisis when its hepatitis C business was squashed by competition.
Xconomy
JUNE 3, 2016
Merck also saw some expected fruits of its 2014 big-ticket acquisition of Cubist Pharmaceuticals wither away this week, as the Supreme Court wouldn’t reverse a decision that shaved years off the patent life of the top-selling antibiotic daptomyicin (Cubicin). billion acquisition of San Diego’s Auspex Pharmaceuticals last year.
socalTECH
NOVEMBER 19, 2018
San Diego-based uCast Global (www.ucastglobal.com), backed by Gary Winnick, is looking to tackle that entire area of content distribution, and is led by startup veteran Dr. Kanaan Jemili. In 2004 and 2005, I was at DivX in San Diego, and I was head of product there. Who are your core customers? Number six are publishers.
Xconomy
JANUARY 25, 2019
After guiding the CRISPR-Cas9 genome-editing startup from scientific breakthrough toward the development of a potential cutting-edge medicine, slogging victoriously through a legendary patent fight , and reaching the cusp of an historic clinical trial , the well-traveled Bosley is cutting out, the company said Tuesday.
Expert insights. Personalized for you.
224 
Let's personalize your content